Ciprofloxacin for Inhalation
( DrugBank: Ciprofloxacin / KEGG DRUG: Ciprofloxacin )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 54 |
299. 嚢胞性線維症
臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
Showing 1 to 10 of 54 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02661438 (ClinicalTrials.gov) | January 12, 201620160112 | 30/12/201520151230 | Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo | Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo Multicenter Summative Usability Study of CiprofloxacinDry Powder for Inhalationin Subjects With Non- ... | Bronchiectasis;Pulmonary Disease, Chronic Obstructive | Drug: Placebo to Ciprofloxacin DPI (BAYQ3939) | Bayer | Novartis | Completed | 40 Years | N/A | All | 46 | N/A | United States |
| 2 | EUCTR2013-005366-19-FR (EUCTR) | 19/05/201520150519 | 22/06/201520150622 | A Multi-centre, Randomised, Double-Blind, Placebo-Controlled Study to evaulate the Safety and Efficacy of Pulmaquin® (ARD-3150, Dual Release Coprofloxacin for Inhalation) in subjects who have a lung infection that includes the bacteria Pseudomonas aeruginosa due to the non-cystic fibrosis bronchiectasis A Multi-centre, Randomised, Double-Blind, Placebo-Controlled Study to evaulate the Safety and Effica ... | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension (ORBIT-4) - Pulmaquin® with Non-Cystic Fibrosis Bronchiectasis (Orbit 4) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficac ... | Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis MedDRA version: 18.0;Level: PT;Classification code 10057582;Term: Lung infection pseudomonal;System Organ Class: 10021881 - Infections and infestations MedDRA version: 18.0;Level: LLT;Classification code 10006446;Term: Bronchiectasis NOS;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiecta ... | Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: CiprofloxacinHydrochloride Other d ... | Aradigm Corporation | NULL | Not Recruiting | Female: yes Male: yes | 255 | Phase 3 | United States;Spain;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Romania;Australia;Germany;Netherlands;New Zealand United States;Spain;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Romania;Australia;Germa ... | ||
| 3 | EUCTR2013-005348-28-PL (EUCTR) | 11/02/201520150211 | 26/11/201420141126 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® (ARD-3150, Dual Release Ciprofloxacin for Inhalation) in subjects who have a lung infection that includes the bacteria Pseudomonas aeruginosa due to non-cystic fibrosis bronchiectasis. This study includes a 28-day open label extension (all patients will receive study drug for the last 28 days of the study). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficac ... | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3) - Pulmaquin® with Non-Cystic Fibrosis Bronchiectasis (ORBIT 3) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficac ... | Chronic lung infections with Pseudomonas aeruginosa in subjects withnon-cystic fibrosis bronchiectasis. MedDRA version: 19.0;Level: PT;Classification code 10057582;Term: Lung infection pseudomonal;System Organ Class: 10021881 - Infections and infestations MedDRA version: 19.0;Level: LLT;Classification code 10006446;Term: Bronchiectasis NOS;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Chronic lung infections with Pseudomonas aeruginosa in subjects withnon-cystic fibrosis bronchiectas ... | Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: CiprofloxacinHydrochloride Other d ... | Aradigm Corporation | NULL | Not Recruiting | Female: yes Male: yes | 255 | Phase 3 | United States;Spain;Ireland;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Australia;South Africa;Latvia;Germany United States;Spain;Ireland;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Austral ... | ||
| 4 | EUCTR2013-005366-19-PL (EUCTR) | 11/02/201520150211 | 26/11/201420141126 | A Multi-centre, Randomised, Double-Blind, Placebo-Controlled Study to evaulate the Safety and Efficacy of Pulmaquin® (ARD-3150, Dual Release Coprofloxacin for Inhalation) in subjects who have a lung infection that includes the bacteria Pseudomonas aeruginosa due to the non-cystic fibrosis bronchiectasis. The study includes a 28-day open-label extension (all patients will receive study drug for the last 28 days of the study). A Multi-centre, Randomised, Double-Blind, Placebo-Controlled Study to evaulate the Safety and Effica ... | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension (ORBIT-4) - Pulmaquin® with Non-Cystic Fibrosis Bronchiectasis (Orbit 4) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficac ... | Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis MedDRA version: 19.0;Level: PT;Classification code 10057582;Term: Lung infection pseudomonal;System Organ Class: 10021881 - Infections and infestations MedDRA version: 19.0;Level: LLT;Classification code 10006446;Term: Bronchiectasis NOS;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiecta ... | Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: CiprofloxacinHydrochloride Other d ... | Aradigm Corporation | NULL | Not Recruiting | Female: yes Male: yes | 255 | Phase 3 | Serbia;United States;Spain;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Australia;Georgia;Germany;New Zealand Serbia;United States;Spain;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Australi ... | ||
| 5 | EUCTR2013-004659-19-SK (EUCTR) | 15/12/201420141215 | 06/10/201420141006 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE) | Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis. - Respire 2 Randomized, double-blind, placebo-controlled, multicenter study comparing CiprofloxacinDPI 32.5 mg B ... | non-CF bronchiectasis MedDRA version: 20.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] non-CF bronchiectasis MedDRA version: 20.0;Level: PT;Classification code 10006445;Term: Bronchiectas ... | Product Name: Ciprofloxacin DPI Product Code: BAYQ3939 INN or Proposed INN: Ciprofloxacin Other descriptive name: CIPROFLOXACIN Product Name: CiprofloxacinDPI Product Code: BAYQ3939 INN or Proposed INN: Ciprofloxacin Other descript ... | Bayer Healthcare AG, D-51368 Leverkusen, Germany | NULL | Not Recruiting | Female: yes Male: yes | 492 | Phase 3 | Portugal;Serbia;United States;Philippines;Hong Kong;Taiwan;Slovakia;Thailand;Russian Federation;Australia;South Africa;Latvia;Netherlands;China;Korea, Republic of;Lithuania;Turkey;Austria;Czech Republic;Argentina;Brazil;Poland;Romania;Bulgaria;Germany Portugal;Serbia;United States;Philippines;Hong Kong;Taiwan;Slovakia;Thailand;Russian Federation;Aust ... | ||
| 6 | EUCTR2011-004208-39-SK (EUCTR) | 18/11/201420141118 | 21/10/201420141021 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE) | Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to fiRst pulmonary exacErbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis. - RESPIRE 1 Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacinDPI 32.5 mg B ... | bronchiectasis MedDRA version: 18.1;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] bronchiectasis MedDRA version: 18.1;Level: PT;Classification code 10006445;Term: Bronchiectasis;Syst ... | Product Name: Ciprofloxacin DPI Product Code: BAYq3939 INN or Proposed INN: Ciprofloxacin Other descriptive name: CIPROFLOXACIN Product Name: CiprofloxacinDPI Product Code: BAYq3939 INN or Proposed INN: Ciprofloxacin Other descript ... | Bayer HealthCare AG | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 3 | Serbia;United States;Slovakia;Spain;Israel;United Kingdom;Italy;France;Argentina;Australia;Denmark;Germany;Latvia;New Zealand;Japan Serbia;United States;Slovakia;Spain;Israel;United Kingdom;Italy;France;Argentina;Australia;Denmark;G ... | ||
| 7 | EUCTR2011-004208-39-LV (EUCTR) | 11/11/201420141111 | 26/09/201420140926 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE) | Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to fiRst pulmonary exacErbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis. - RESPIRE 1 Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacinDPI 32.5 mg B ... | bronchiectasis MedDRA version: 17.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] bronchiectasis MedDRA version: 17.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;Syst ... | Product Name: Ciprofloxacin DPI Product Code: BAYq3939 INN or Proposed INN: Ciprofloxacin Other descriptive name: CIPROFLOXACIN Product Name: CiprofloxacinDPI Product Code: BAYq3939 INN or Proposed INN: Ciprofloxacin Other descript ... | Bayer HealthCare AG | NULL | Not Recruiting | Female: yes Male: yes | 400 | Serbia;United States;Slovakia;Spain;Israel;United Kingdom;Italy;France;Argentina;Australia;Denmark;Latvia;Germany;New Zealand;Japan Serbia;United States;Slovakia;Spain;Israel;United Kingdom;Italy;France;Argentina;Australia;Denmark;L ... | |||
| 8 | EUCTR2013-004659-19-LV (EUCTR) | 11/11/201420141111 | 30/09/201420140930 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE) | Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis. - Respire 2 Randomized, double-blind, placebo-controlled, multicenter study comparing CiprofloxacinDPI 32.5 mg B ... | non-CF bronchiectasis MedDRA version: 17.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] non-CF bronchiectasis MedDRA version: 17.0;Level: PT;Classification code 10006445;Term: Bronchiectas ... | Product Name: Ciprofloxacin DPI Product Code: BAYQ3939 INN or Proposed INN: Ciprofloxacin Other descriptive name: CIPROFLOXACIN Product Name: CiprofloxacinDPI Product Code: BAYQ3939 INN or Proposed INN: Ciprofloxacin Other descript ... | Bayer Healthcare AG, D-51368 Leverkusen, Germany | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 3 | Portugal;Serbia;United States;Philippines;Hong Kong;Taiwan;Slovakia;Thailand;Russian Federation;Australia;South Africa;Netherlands;Latvia;China;Korea, Republic of;Lithuania;Turkey;Austria;Czech Republic;Argentina;Brazil;Poland;Romania;Bulgaria;Germany Portugal;Serbia;United States;Philippines;Hong Kong;Taiwan;Slovakia;Thailand;Russian Federation;Aust ... | ||
| 9 | EUCTR2013-005348-28-IE (EUCTR) | 07/11/201420141107 | 11/09/201420140911 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® (ARD-3150, Dual Release Ciprofloxacin for Inhalation) in subjects who have a lung infection that includes the bacteria Pseudomonas aeruginosa due to non-cystic fibrosis bronchiectasis. This study includes a 28-day open-label extension (all patients will receive study drug for the last 28 days of the study). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficac ... | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3) - Pulmaquin® with Non-Cystic Fibrosis Bronchiectasis (ORBIT 3) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficac ... | Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiectasis. MedDRA version: 19.0;Level: PT;Classification code 10057582;Term: Lung infection pseudomonal;System Organ Class: 10021881 - Infections and infestations MedDRA version: 19.0;Level: LLT;Classification code 10006446;Term: Bronchiectasis NOS;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Chronic lung infections with Pseudomonas aeruginosa in subjects with non-cystic fibrosis bronchiecta ... | Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE INN or Proposed INN: Ciprofloxacin Hydrochloride Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE Product Name: Pulmaquin® Product Code: ARD-3150 INN or Proposed INN: CiprofloxacinHydrochloride Other d ... | Aradigm Corporation | NULL | Not Recruiting | Female: yes Male: yes | 255 | Phase 3 | United States;Spain;Ireland;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Australia;South Africa;Germany;Latvia United States;Spain;Ireland;Israel;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Austral ... | ||
| 10 | EUCTR2013-004659-19-BG (EUCTR) | 26/09/201420140926 | 05/08/201420140805 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non–CF BE) | Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in subjects with non–cystic fibrosis bronchiectasis. - Respire 2 Randomized, double-blind, placebo-controlled, multicenter study comparing CiprofloxacinDPI 32.5 mg B ... | non-CF bronchiectasis MedDRA version: 19.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] non-CF bronchiectasis MedDRA version: 19.0;Level: PT;Classification code 10006445;Term: Bronchiectas ... | Product Name: Ciprofloxacin DPI Product Code: BAYQ3939 INN or Proposed INN: Ciprofloxacin Other descriptive name: CIPROFLOXACIN Product Name: CiprofloxacinDPI Product Code: BAYQ3939 INN or Proposed INN: Ciprofloxacin Other descript ... | Bayer AG | NULL | Not Recruiting | Female: yes Male: yes | 492 | Phase 3 | Portugal;Serbia;United States;Philippines;Hong Kong;Taiwan;Slovakia;Thailand;Russian Federation;Australia;South Africa;Netherlands;Latvia;China;Korea, Republic of;Lithuania;Turkey;Austria;Czech Republic;Argentina;Brazil;Poland;Romania;Bulgaria;Germany Portugal;Serbia;United States;Philippines;Hong Kong;Taiwan;Slovakia;Thailand;Russian Federation;Aust ... |